ClinicalTrials.gg
CompletedNCT01543529Updated May 10, 2017

A Pharmacodynamic and Pharmacokinetic Study of RO4917838 in Healthy Volunteers

A Phase 1 interventional study of RO4917838 and Placebo to RO4917838 in Healthy Volunteer, sponsored by Hoffmann-La Roche. Completed at 1 site in France. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-10.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This single-center, randomized, double-blind, four-period crossover study will investigate the effect of alcohol on the pharmacodynamics and pharmacokinetics of RO4917838 in healthy volunteers. Healthy volunteers will receive 4 treatments in a randomized order: single dose of RO4917838 and alcohol, RO4917838 and non-alcoholic drink, placebo to RO4917838 and alcohol, and placebo to RO4917838 and non-alcoholic drink.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult healthy volunteers, 18 to 45 years, inclusive
  • (BMI) 18 to 30 kg/m2, inclusive
  • Non-smoker or smoker of fewer than 10 cigarettes per day
  • Females, who are not menopausal must agree to use two adequate methods of

Exclusion criteria

Exclusion Criteria:

  • Any current medical condition or disease that would render the volunteer unsuitable for the study, or would place the volunteer at undue risk
  • History of alcoholism
  • History of drug abuse and/or addiction within one year of study start
  • History of any significant disease (e.g., cardiovascular, hepatic, renal) or cancer
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
25 participants (actual)

Study arms

  • Active comparator
    RO4917838 + non-alcoholic drink

    Drug: RO4917838

  • Experimental
    RO4917838 + alcohol

    Drug: RO4917838 · Other: Alcohol

  • Placebo comparator
    RO4917838 placebo + alcohol

    Drug: Placebo to RO4917838 · Other: Alcohol

  • Placebo comparator
    RO4917838 placebo + non-alcoholic drink

    Drug: Placebo to RO4917838

Interventions

  • Single dose of RO4917838

  • DrugPlacebo to RO4917838

    Single dose of placebo to RO4917838

  • OtherAlcohol

    Standard alcoholic drink

06

What researchers measure

Primary outcomes

  1. Effect of alcohol on pharmacodynamics (Cognitive test battery) of RO4917838

    Time frame: Day 1 of each treatment period

Secondary outcomes

  1. Effect of alcohol on pharmacokinetics (Area under the concentration time curve) of RO4917838

    Time frame: Days 1, 2, 3, 4, 6, and 8 of each treatment period

  2. Safety: Incidence of adverse events

    Time frame: Approximately 4 months

07

Study locations

1 site
  • BIOTRIAL
    Rennes, 35042, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2012 to primary completion in Jun 2012, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2012
First posted
Mar 5, 2012
StartActual
Feb 28, 2012
Primary completionActual
Jun 4, 2012
CompletionActual
Jun 4, 2012
Last update
May 10, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01543529
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 5, 2012
Start date
Feb 28, 2012
Primary completion
Jun 4, 2012
Completion
Jun 4, 2012
Last update
May 10, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bitopertin

Start the discussion